Study The Relationship Between Intercellular Adhesion Molecules( ICAM) And Insulin Resistance Among Type 2 Egyptian Diabetic Patients With Nephropathy

2010 ◽  
Vol 27 (2) ◽  
Author(s):  
M Shafik ◽  
MS Shoman ◽  
I Emara ◽  
H Elmonem ◽  
H Mohamed saad
Keyword(s):  
Insulin Resistance ◽  
Adhesion Molecules ◽  
Intercellular Adhesion ◽  
Diabetic Patients ◽  
Intercellular Adhesion Molecules ◽  
The Relationship

scholarly journals The Relationship between Hepatic Steatosis, inflammation and insulin Resistance in type 2 Diabetes with Metabolic Imbalance

2019 ◽  
Vol 16 (4) ◽  
pp. 13-25
Author(s):  
Elena-Daniela Grigorescu ◽  
Mariana Floria ◽  
Cristina Mihaela Lăcătușu ◽  
Bogdan Mircea-Mihai ◽  
Ioana Creţu ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Hepatic Steatosis ◽  
Diabetic Patients ◽  
Alcoholic Fatty Liver ◽  
Bidirectional Relationship ◽  
Metabolic Imbalance ◽  
History Of ◽  
The Relationship

AbstractAim. Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are in a bidirectional relationship. This prospective study focused on associations between parameters common to the pathogenesis of insulin resistance, inflammation and hepatic steatosis in T2DM patients with metabolic imbalance.Methods. We used clinical data, insulin resistance and inflammation indices, and hepatic steatosis markers from 120 patients.Results. The patients (44% men, mean age 58) had a mean body mass index (BMI) of 32 kg/m2 and mean T2DM history of 6 years. With exceptions, significant correlations were found between metabolic, inflammatory and hepatic parameters.Conclusions. In T2DM patients with poor glycemic control, hepatic steatosis correlates significantly with insulin resistance and inflammation. Increased prevalence and poor prognosis of these diseases together justify the need for NAFLD screening of diabetic patients.

scholarly journals Intermittent fasting: is there a role in the treatment of diabetes? A review of the literature and guide for primary care physicians

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Michael Albosta ◽  
Jesse Bakke
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Treatment Option ◽  
Primary Care Physicians ◽  
Case Series ◽  
Current Evidence ◽  
Intermittent Fasting ◽  
Diabetic Patients ◽  
Medicinal Treatment

Abstract Background Type 2 Diabetes is a metabolic disorder characterized by hyperglycemia that causes numerous complications with significant long-term morbidity and mortality. The disorder is primarily due to insulin resistance particularly in liver, skeletal muscle, and adipose tissue. In this review, we detail the hormonal mechanisms leading to the development of diabetes and discuss whether intermittent fasting should be considered as an alternative, non-medicinal treatment option for patients with this disorder. Methods We searched PubMed, Ovid MEDLINE, and Google Scholar databases for review articles, clinical trials, and case series related to type 2 diabetes, insulin resistance, and intermittent fasting. Articles were carefully reviewed and included based on relevance to our topic. We excluded abstracts and any non-English articles. Results The majority of the available research demonstrates that intermittent fasting is effective at reducing body weight, decreasing fasting glucose, decreasing fasting insulin, reducing insulin resistance, decreasing levels of leptin, and increasing levels of adiponectin. Some studies found that patients were able to reverse their need for insulin therapy during therapeutic intermittent fasting protocols with supervision by their physician. Conclusion Current evidence suggests that intermittent fasting is an effective non-medicinal treatment option for type 2 diabetes. More research is needed to delineate the effects of intermittent fasting from weight loss. Physicians should consider educating themselves regarding the benefits of intermittent fasting. Diabetic patients should consult their physician prior to beginning an intermittent fasting regimen in order to allow for appropriate oversight and titration of the patients medication regimen during periods of fasting.

The effect of insulin resistance on postprandial triglycerides in Korean type 2 diabetic patients

2012 ◽  
Vol 51 (1) ◽  
pp. 15-22 ◽  
Author(s):  
Kyeong Hye Park ◽  
Kwang Joon Kim ◽  
Byung-Wan Lee ◽  
Eun Seok Kang ◽  
Bong Soo Cha ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Postprandial Triglycerides ◽  
Korean Type ◽  
Type 2 Diabetic

Insulin Resistance Is Associated with Increased Circulating Level of Thrombin-Activatable Fibrinolysis Inhibitor in Type 2 Diabetic Patients

2002 ◽  
Vol 87 (2) ◽  
pp. 660-665 ◽  
Author(s):  
Yasuko Hori ◽  
Esteban C. Gabazza ◽  
Yukata Yano ◽  
Akira Katsuki ◽  
Koji Suzuki ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Plasma Levels ◽  
Common Finding ◽  
Diabetic Patients ◽  
Thrombin Activatable Fibrinolysis Inhibitor ◽  
Type 2 Diabetic Patients ◽  
Visceral Fat Area ◽  
Type 2 Dm ◽  
Fibrinolysis Inhibitor

Hypofibrinolysis is a common finding in patients with diabetes mellitus (DM) and obesity and a risk factor for the development of cardiovascular disease. Recently, a new potent inhibitor of fibrinolysis, the thrombin-activatable fibrinolysis inhibitor (TAFI) has been isolated and characterized from human plasma. The present study was undertaken to assess the activity and circulating level of TAFI and its relation to fibrinolytic function and obesity in patients with type 2 DM. Fifty-seven patients with type 2 DM (38 men, 19 women) were enrolled in this study. DM patients were categorized in age-matched obese [body mass index (BMI) ≥ 25] and nonobese (BMI < 25) groups. The plasma concentration and activity of TAFI were significantly (P < 0.05) higher in DM patients than in healthy controls. The plasma levels and activity of TAFI were significantly (P < 0.05) elevated in obese DM patients compared with nonobese DM and nonobese healthy subjects. RT-PCR demonstrated the expression of TAFI in human adipose tissue and in human endothelial cells. The plasma levels of TAFI were independently and significantly correlated with glucose intolerance (HbA1c), with obesity (BMI, visceral fat area), and with an indicator of insulin resistance (glucose infusion rate). This study showed that increased circulating level of TAFI may be an important causative factor of hypofibrinolysis in patients with type 2 diabetes, obesity and insulin resistance.

Sign in / Sign up

Export Citation Format

Share Document